Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Opsonophagocytosis of Pseudomonas aeruginosa treated with antiflagellar serum.

Literature DB >> 3119502

Opsonophagocytosis of Pseudomonas aeruginosa treated with antiflagellar serum.

Abstract

Hyperimmune rabbit flagellar antisera were shown to enhance opsonophagocytosis of Pseudomonas aeruginosa by mouse peritoneal polymorphonuclear leukocytes. This response was specific for flagellar immunoglobulin G as indicated by cross-opsonization experiments.

Entities: Species

Mesh：

Substances：

Year: 1987 PMID： 3119502 PMCID： PMC260050 DOI： 10.1128/iai.55.12.3204-3206.1987

Source DB: PubMed Journal: Infect Immun ISSN： 0019-9567 Impact factor: 3.441

15 in total

1. Immunotherapeutic potential of monoclonal antibodies against Pseudomonas aeruginosa protein F.

Authors: R E Hancock; L M Mutharia; E C Mouat
Journal: Eur J Clin Microbiol Date: 1985-04 Impact factor: 3.267

Review 2. Phagocytosis of microorganisms.

Authors: M A Horwitz
Journal: Rev Infect Dis Date: 1982 Jan-Feb

3. Human immunity to Pseudomonas aeruginosa. II. Relationship between heat-stable opsonins and type-specific lipopolysaccharides.

Authors: L S Young
Journal: J Infect Dis Date: 1972-09 Impact factor: 5.226

4. Characterization of the human immune response to a polysaccharide vaccine from Pseudomonas aeruginosa.

Authors: G B Pier; D M Thomas
Journal: J Infect Dis Date: 1983-08 Impact factor: 5.226

5. Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa.

Authors: G B Pier
Journal: J Clin Invest Date: 1982-02 Impact factor: 14.808

6. Flagellar preparations from Pseudomonas aeruginosa: animal protection studies.

Authors: I A Holder; R Wheeler; T C Montie
Journal: Infect Immun Date: 1982-01 Impact factor: 3.441

7. Role of lipopolysaccharide in opsonization and phagocytosis of Pseudomonas aeruginosa.

Authors: W Engels; J Endert; M A Kamps; C P van Boven
Journal: Infect Immun Date: 1985-07 Impact factor: 3.441

8. Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans.

Authors: M Pollack
Journal: J Infect Dis Date: 1983-06 Impact factor: 5.226

9. Simple model for the study of Pseudomonas aeruginosa infections in leukopenic mice.

Authors: S J Cryz; E Fürer; R Germanier
Journal: Infect Immun Date: 1983-03 Impact factor: 3.441

10. Nonopsonic phagocytosis of nonmucoid Pseudomonas aeruginosa by human neutrophils and monocyte-derived macrophages is correlated with bacterial piliation and hydrophobicity.

Authors: D P Speert; B A Loh; D A Cabral; I E Salit
Journal: Infect Immun Date: 1986-07 Impact factor: 3.441

12 in total

1. Pseudomonas aeruginosa immunotherapy.

Authors: J E Pennington
Journal: Eur J Clin Microbiol Infect Dis Date: 1990-06 Impact factor: 3.267

2. Effect of antiflagellar human monoclonal antibody on gut-derived Pseudomonas aeruginosa sepsis in mice.

Authors: T Matsumoto; K Tateda; S Miyazaki; N Furuya; A Ohno; Y Ishii; Y Hirakata; K Yamaguchi
Journal: Clin Diagn Lab Immunol Date: 1999-07

3. Generation and characterization of murine antiflagellum monoclonal antibodies that are protective against lethal challenge with Pseudomonas aeruginosa.

Authors: M J Rosok; M R Stebbins; K Connelly; M E Lostrom; A W Siadak
Journal: Infect Immun Date: 1990-12 Impact factor: 3.441

4. Pseudomonas aeruginosa flagellar antibodies in patients with cystic fibrosis.

Authors: T R Anderson; T C Montie; M D Murphy; V P McCarthy
Journal: J Clin Microbiol Date: 1989-12 Impact factor: 5.948

5. Pseudomonas aeruginosa regulates flagellin expression as part of a global response to airway fluid from cystic fibrosis patients.

Authors: Matthew C Wolfgang; Jeevan Jyot; Andrew L Goodman; Reuben Ramphal; Stephen Lory
Journal: Proc Natl Acad Sci U S A Date: 2004-04-14 Impact factor: 11.205

6. Therapeutic effects of a human antiflagella monoclonal antibody in a neutropenic murine model of Pseudomonas aeruginosa pneumonia.

Authors: K Oishi; F Sonoda; A Iwagaki; P Ponglertnapagorn; K Watanabe; T Nagatake; A Siadak; M Pollack; K Matsumoto
Journal: Antimicrob Agents Chemother Date: 1993-02 Impact factor: 5.191

7. Inhibitory activity on bacterial motility and in vivo protective activity of human monoclonal antibodies against flagella of Pseudomonas aeruginosa.

Authors: H Ochi; H Ohtsuka; S Yokota; I Uezumi; M Terashima; K Irie; H Noguchi
Journal: Infect Immun Date: 1991-02 Impact factor: 3.441

8. Monoclonal antibody-mediated protection and neutralization of motility in experimental Proteus mirabilis infection.

Authors: R C Harmon; R L Rutherford; H M Wu; M S Collins
Journal: Infect Immun Date: 1989-07 Impact factor: 3.441

9. Functional Activity of Antibodies Directed towards Flagellin Proteins of Non-Typhoidal Salmonella.

Authors: Girish Ramachandran; Sharon M Tennant; Mary A Boyd; Jin Y Wang; Mohan E Tulapurkar; Marcela F Pasetti; Myron M Levine; Raphael Simon
Journal: PLoS One Date: 2016-03-21 Impact factor: 3.240

10. Cloning, Expression, and Purification of Pseudomonas aeruginosa Flagellin, and Characterization of the Elicited Anti-Flagellin Antibody.

Authors: Bahador Behrouz; Nour Amirmozafari; Nima Khoramabadi; Mahboobeh Bahroudi; Parisa Legaee; Mehdi Mahdavi
Journal: Iran Red Crescent Med J Date: 2016-06-12 Impact factor: 0.611